Cassava Sciences, Inc. Warrant
Not enough financial coverage to compute a composite score for SAVAW. This is typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available data still render below.
Companywww.cassavasciences.com
Cassava Sciences, Inc. , a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
- CEO
- Richard Jon Barry
- IPO
- 2024
- Employees
- 30
- HQ
- Austin, TX, US
Price Chart
Performance & Tape
- 52W High
- $11.02
- 52W Low
- $0.02
- 50D MA
- $3.49
- 200D MA
- $4.93
- Beta
- -0.76
- Avg Volume
- 331.00K
Get TickerSpark's AI analysis on SAVAW
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SAVAW Coverage
We haven't published any research on SAVAW yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SAVAW Report →